Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
KRX:207940
Price:
750 000 KRW
-1.32%
Updated:
Jun 10, 2024
Samsung Biologics Co Ltd
Capital Expenditures
|
Samsung Biologics Co Ltd
Capital Expenditures Peer Comparison
Comparables:
P
087010
S
237690
F
220100
L
141080
C
268600
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Capital Expenditures
-₩740.5B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Capital Expenditures
-₩1.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Capital Expenditures
-₩40.7B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Capital Expenditures
-₩2.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Capital Expenditures
-₩2.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-6%
|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Capital Expenditures
-₩17.6B
|
CAGR 3-Years
-190%
|
CAGR 5-Years
-119%
|
CAGR 10-Years
N/A
|
See Also
What is Samsung Biologics Co Ltd's Capital Expenditures?
Capital Expenditures
-740.5B
KRW
-740.5B
KRW
Based on the financial report for Mar 31, 2024, Samsung Biologics Co Ltd's Capital Expenditures amounts to -740.5B KRW.
What is Samsung Biologics Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-25%
-25%
Over the last year, the Capital Expenditures growth was 37%. The average annual Capital Expenditures growth rates for Samsung Biologics Co Ltd have been -52% over the past three years , -25% over the past five years .
You don't have any saved screeners yet
